Contrasting Omnicell (OMCL) and its Rivals
Omnicell (NASDAQ: OMCL) is one of 18 public companies in the “Medical Software & Technology Services” industry, but how does it weigh in compared to its rivals? We will compare Omnicell to related businesses based off the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.
This table compares Omnicell and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Omnicell and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Omnicell||$680.15 million||$42.68 million||-227.27|
|Omnicell Competitors||$375.89 million||$34.57 million||9.62|
Omnicell has higher revenue and earnings than its rivals. Omnicell is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently the more affordable than other companies in its industry.
Volatility & Risk
Omnicell has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Omnicell’s rivals have a beta of 1.33, meaning that their average stock price is 33% more volatile than the S&P 500.
Institutional & Insider Ownership
96.4% of Omnicell shares are held by institutional investors. Comparatively, 63.2% of shares of all “Medical Software & Technology Services” companies are held by institutional investors. 3.8% of Omnicell shares are held by insiders. Comparatively, 24.4% of shares of all “Medical Software & Technology Services” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a summary of recent ratings and price targets for Omnicell and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Omnicell currently has a consensus target price of $51.57, indicating a potential upside of 3.14%. All “Medical Software & Technology Services” companies have a potential upside of 16.99%. Given Omnicell’s rivals higher possible upside, analysts clearly believe Omnicell has less favorable growth aspects than its rivals.
Omnicell beats its rivals on 8 of the 12 factors compared.
Omnicell, Inc. provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment is engaged in the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems and related software. The Medication Adherence segment includes the development, manufacturing and selling of consumable medication blister cards, packaging equipment, medication synchronization platform, and ancillary products and services. Its products are used to manage medication administration outside of the hospital setting and include medication adherence products sold under the brand name MTS, Surgichem, SureMed and the Omnicell brand.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.